

Curriculum Vitae



Personal Information

First name: Martina	Partner No.: 6 MLU
Surname: Vetter	Role in the consortium: Research task member
Title/s: Dr. rer. nat.	
Gender: Female	
Nationality: German	
Official name of the institution: Martin Luther University Halle Wittenberg	Phone: +49 345 557 1336
Official name of your department: Department of Gynaecology	Fax: +49 345 557 1551
City: Halle (Saale)	Email: martina.vetter@uk-halle.de
Country: Germany	Legal status: Academic Public

Major Scientific Expertise

- Laboratory expertise in molecular biology for translational research (breast cancer)

Employment history

- since 2003 biologist in the laboratory of the Dpt. of Gynecology Martin Luther University Halle Wittenberg for translational research and biobanking

Qualifications

- PhD Thesis in molecular biology (1994)

Scientific Activities, Achievements and Awards

Since the beginning of my activities concerning breast cancer research in Ethiopia led by my colleague Eva Kantelhardt, I have participated in all projects from the laboratory side. I am involved in the design of the projects and the supervision of MD students working in Ethiopia as well as researchers from Ethiopia working in our laboratory and at our clinic in Halle. I am Co-PI of one of the projects concerning estrogen receptor-negative breast cancer in Ethiopia. Being a biologist in the research laboratory of gynecology, I am responsible for the biobanking of tumor tissue and liquids of cancer patients. My specific research focus in gynecological oncology is on the evaluation of tumor biological parameters (PAM50 assay for intrinsic subtyping) for estimation disease prognosis and prediction of therapy response and/or patient outcome as well as bringing new prognostic tests (uPA/PAI-1) into the clinical routine. Quality assurance of all laboratory work is managed by me.

Research Grants

HER2Low: Targeting the ERBB-module in HER2-low breast cancer: Mathematical modeling of response towards drugs targeting HER2, EGFR and ERBB3 to personalize breast cancer treatment, BMBF 031A429E

Publications

1. Hartung C, Porsch M, Stückrath K, Kaufhold S, Staeger MS, Hanf V, Lantsch T, Uleer C, Peschel S, John J, Pöhler M, Weigert E, Buchmann J, Bürrig K-F, Schüler K, Bethmann D, Große I, **Kantelhardt EJ**, Thomssen C, **Vetter M** (2021) Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping. *Breast care (Basel, Switzerland)* 16:637–647. doi:10.1159/000519255
2. **Bauer M, Kantelhardt EJ**, Stiewe T, Nist A, Mernberger M, Politt K, Hanf V, Lantsch T, Uleer C, Peschel S, John J, Buchmann J, Weigert E, Bürrig K-F, Wickenhauser C, Thomssen C, Bartel F, **Vetter M** (2019) Specific allelic variants of SNPs in the MDM2 and MDMX genes are associated with earlier tumor onset and progression in Caucasian breast cancer patients. *Oncotarget* 10:1975–1992. doi:10.18632/oncotarget.26768
3. Bachmann HS, Jung D, Link T, Arnold A, **Kantelhardt E**, Thomssen C, Wimberger P, **Vetter M**, Kuhlmann JD (2022) FNTB Promoter Polymorphisms Are Independent Predictors of Survival in Patients with Triple Negative Breast Cancer. *Cancers* 14. doi:10.3390/cancers14030468
4. Berdiel-Acer M, Maia A, Hristova Z, Borgoni S, **Vetter M**, Burmester S, Becki C, Michels B, Abnaof K, Binenbaum I, Bethmann D, Chatziioannou A, Hasmann M, Thomssen C, Espinet E, Wiemann S (2021) Stromal NRG1 in luminal breast cancer defines pro-fibrotic and migratory cancer-associated fibroblasts. *Oncogene* 40:2651–2666. doi:10.1038/s41388-021-01719-3
5. Reibold CF, Tariku W, Eber-Schulz P, Getachew S, **Addisie A**, Unverzagt S, **Wienke A**, Hauptmann S, Wickenhauser C, **Vetter M**, Jemal A, Thomssen C, **Kantelhardt EJ** (2021) Adherence to Newly Implemented Tamoxifen Therapy for Breast Cancer Patients in Rural Western Ethiopia. *Breast care (Basel, Switzerland)* 16:484–490. doi:10.1159/000512840